Product category:
Pharmaceutical Processing News
News Release from: Amersin Life Sciences
Edited by the Processingtalk Editorial
Team on 18 November 2004
Hubei Pharmaceutical renamed Amersin
Life Sciences
Hubei Pharmaceutical Group Ltd announced today that the company name will be changed to Amersin Life Sciences Corporation, to reflect the business and diversification plans of the company
Hubei Pharmaceutical Group Ltd announced today that the Board of Directors and shareholders have acted to approve an amendment to the articles of the corporation to change its name This is being done to more closely reflect the business and diversification plans of the company
This article was originally published on Processingtalk on 9 Jul 2003 at 8.00am (UK)
Related stories
Robot army for Land Rover
ABB, the global power and automation technologies group, announced today that it has won an order from Ford Premier Automotive Group to supply 186 industrial robots to Land Rover
ABB creates new Nationwide instrumentation network
A new comprehensive instrumentation supply and service network has been created by ABB to serve customers throughout the UK: the Instrumentation Alliance comprises five carefully selected partners
Under its new name, Amersin Life Sciences Corporation, the company will continue to expand upon its interests in China to cover all facets of pharmaceutical life sciences from raw materials through dosage form production, distribution and, in some specialised domestic markets, dispensing.
"We will continue to build investor equity through strategic acquisition and vertical integration" said the company's president, Reid Li, who went on to say "The key to emerging as one of the leading American corporations with interests in the Chinese pharmaceuticals sector is the American-Sino joint venture structures we employ to implement acquisition.
They provide for continuity of successful management and business practices, while encouraging and providing opportunities to mentor western styled entrepreneurship.
Our success lies in our ability to strategically identify acquisition candidates and in the synergy with which we integrate them.
We are focused on profitability and delivering to our shareholders a tightly integrated set of holdings with domestic and export revenue streams".
The company's shares trade on the Over the Counter exchange in the United States under the trading symbol HBEI.
The name change will take effect once SEC and regulatory requirements are complete.
At that time a new CUSIP number and trading symbol will be assigned.
It is anticipated that the process will be complete within 30 days.
There is no need for shareholders to take any action.
Share certificates bearing the Hubei name will be equivalent to, and will be exchanged for, share certificates bearing the Amersin name as they are encountered by the transfer agent.
Concurrent with the name change, and supported by our recent shift to profitability, we will work to broaden investor awareness worldwide.
The company expects to achieve and report other significant milestones in the near future.
• Amersin Life Sciences: contact details and other news
• Email this article to a colleague
• Register for the free Processingtalk email newsletter
• Processingtalk Home Page
Search the Pro-Talk network of sites
